Literature DB >> 16048995

Strain-specific expression levels of pbp4 exist in isolates of glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA.

M Wootton, P M Bennett, A P MacGowan, T R Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16048995      PMCID： PMC1196220          DOI： 10.1128/AAC.49.8.3598-3599.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1999-12       Impact factor: 3.490

2.  Absence of mutation in the region (nt. 710-1010) of pbp4 gene in clinical isolates of Staphylococcus aureus with low-level teicoplanin resistance.

Authors:  Y Park; E J Oh; S O Lee; B K Kim
Journal:  Diagn Microbiol Infect Dis       Date:  2001-04       Impact factor: 2.803

3.  Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  B Moreira; S Boyle-Vavra; B L deJonge; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus.

Authors:  K Sieradzki; M G Pinho; A Tomasz
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

5.  Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus.

Authors:  J E Finan; G L Archer; M J Pucci; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  A membrane enzyme from Staphylococcus aureus which catalyzes transpeptidase, carboxypeptidase, and penicillinase activities.

Authors:  J W Kozarich; J L Strominger
Journal:  J Biol Chem       Date:  1978-02-25       Impact factor: 5.157

7.  Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin.

Authors:  Andrea Reipert; Kerstin Ehlert; Thomas Kast; Gabriele Bierbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis.

Authors:  K Sieradzki; A Tomasz
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

9.  Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages.

Authors:  Robin A Howe; Alastair Monk; Mandy Wootton; Timothy R Walsh; Mark C Enright
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883
  9 in total
  4 in total

1.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Biosynthetic pathway for mannopeptimycins, lipoglycopeptide antibiotics active against drug-resistant gram-positive pathogens.

Authors:  Nathan A Magarvey; Brad Haltli; Min He; Michael Greenstein; John A Hucul
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.

Authors:  Adrien Fischer; Soo-Jin Yang; Arnold S Bayer; Ali R Vaezzadeh; Sébastien Herzig; Ludwig Stenz; Myriam Girard; George Sakoulas; Alexander Scherl; Michael R Yeaman; Richard A Proctor; Jacques Schrenzel; Patrice François
Journal:  J Antimicrob Chemother       Date:  2011-05-28       Impact factor: 5.790

Review 4.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.